Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
About this item
Full title
Author / Creator
Kumar, Dhiraj , Lisok, Ala , Dahmane, Elyes , McCoy, Matthew , Shelake, Sagar , Chatterjee, Samit , Allaj, Viola , Sysa-Shah, Polina , Wharram, Bryan , Lesniak, Wojciech G , Tully, Ellen , Gabrielson, Edward , Jaffee, Elizabeth M , Poirier, John T , Rudin, Charles M , Gobburu, Jogarao Vs , Pomper, Martin G and Nimmagadda, Sridhar
Publisher
United States: American Society for Clinical Investigation
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Society for Clinical Investigation
Subjects
More information
Scope and Contents
Contents
Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we show that target engagement and tumor-residence kinetics of antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified no...
Alternative Titles
Full title
Peptide-based PET quantifies target engagement of PD-L1 therapeutics
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6355241
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6355241
Other Identifiers
ISSN
0021-9738
E-ISSN
1558-8238
DOI
10.1172/JCI122216
